|Ms. Anita Johansen||Chief Exec. Officer||2.39M||N/A||1972|
|Mr. Henrik Lundkvist||Chief Financial Officer||N/A||N/A||1977|
|Von Carlson||VP of Operations||N/A||N/A||1970|
|Ms. Basudha Bhattarai-Johansson||VP of Human Relations & Sustainability||N/A||N/A||1983|
|Ms. Veronica Dong||Head of APAC - Singapore||N/A||N/A||N/A|
|Ms. Magdolna Dimén||Group Controller||N/A||N/A||N/A|
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, the Middle East, Africa, Asia, and Pacific. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; University of Gothenburg to investigate the effects of probiotic strain LP299V on iron absorption; Wageningen University & Research to understand the molecular interactions occurring between microbes and its hosts; University of Umeå to investigate the effects of the strain LP299V on iron status in female athletes; and University of Aberdeen to characterize bacterial isolates with next generation probiotics. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
Probi AB (publ)’s ISS governance QualityScore as of 1 September 2023 is 3. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 6; Compensation: 3.